Mosaic ImmunoEngineering (CPMV) Cash & Equivalents (2010 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Cash & Equivalents of $72.0 for Q1 2026, down 99.92% year-over-year from $85930.0 in Q1 2025, and down 98.01% quarter-over-quarter from $3622.0 in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Cash & Equivalents (2010 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $72.0 for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 99.92% year-over-year to $72.0; the TTM figure through Mar 2026 stood at $72.0 (down 99.92% YoY), while the FY2025 annual figure was $3622.0, down 96.85% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $72.0, down from $3622.0 in the prior quarter.
- The five-year high for Cash & Equivalents was $384137.0 in Q3 2022, with the low at $72.0 in Q1 2026.
- The 5-year median for Cash & Equivalents is $115019.0 (2024), against an average of $144185.3.
- The sharpest annual moves came in 2025 and 2026: Cash & Equivalents soared 1335.0% in 2025, then slumped 99.92% in 2026.
- Mosaic ImmunoEngineering's Cash & Equivalents stood at $220645.0 in 2022, then slipped by 29.22% to $156178.0 in 2023, then slipped by 26.35% to $115019.0 in 2024, then tumbled by 96.85% to $3622.0 in 2025, then tumbled by 98.01% to $72.0 in 2026.
- Business Quant data shows CPMV's Cash & Equivalents at $72.0 in Q1 2026, $3622.0 in Q4 2025, and $31761.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | 72.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.00 |
| Dec 31, 2025 | 3,622.00 |
| Sep 30, 2025 | 31,761.00 |
| Jun 30, 2025 | 53,583.00 |
| Mar 31, 2025 | 85,930.00 |
| Dec 31, 2024 | 115,019.00 |
| Sep 30, 2024 | 5,736.00 |
| Jun 30, 2024 | 3,734.00 |
| Mar 31, 2024 | 65,039.00 |
| Dec 31, 2023 | 156,178.00 |
| Sep 30, 2023 | 252,898.00 |
| Jun 30, 2023 | 362,970.00 |
| Mar 31, 2023 | 125,777.00 |
| Dec 31, 2022 | 220,645.00 |
| Sep 30, 2022 | 384,137.00 |
| Jun 30, 2022 | 205,994.00 |
| Mar 31, 2022 | 378,055.00 |
| Dec 31, 2021 | 226,142.00 |
| Sep 30, 2021 | 393,121.00 |
| Jun 30, 2021 | 582,304.00 |